Company

Werewolf Therapeutics, Inc.

Cambridge biotech developing cancer biotherapeutics based on its proprietary INDUKINE molecules that enhance the immune response.

About

Werewolf Therapeutics, Inc. was founded in 2017 and is headquartered in Cambridge, US. The company uses its proprietary INDUKINE molecules, conditionally activated proinflammatory immune modulators, to enhance the body's immune response against cancer. It completed an IPO on April 29, 2021, raising USD 120 mn, and reported 2024 revenue of USD 1.885 mn and EBITDA of USD -73.594 mn. Its IPO proceeds are funding phase 1 studies of product candidates WTX-124 and WTX-330.

2Funding rounds

10Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in